Senores Pharmaceuticals Limited — PPTs, 14-05-2026: Investor Presentation

Senores Pharma delivered strong FY26 results with Total Income growing 61.8% to Rs. 664 Cr. PAT surged 108% to Rs. 121.5 Cr, and EBITDA jumped 96% to Rs. 199.6 Cr, with margins improving significantly (EBITDA 30.1%, PAT 18.3%). Regulated Markets led revenue (64% of total), growing 74.6%. Emerging Markets and Branded Generics also showed steady growth. Operating cash flow improved significantly to Rs. 7.52 Cr.

Key strategic moves include acquiring 51% in US-based Zoraya Pharma for vertical integration and 75% in Apnar Pharma. A 70% joint venture, Amerisyn, entered the US federal market. The company boasts a robust pipeline of 51 approved ANDAs (30 yet to launch) for regulated markets and plans to expand API manufacturing capacity from 25 MTPA to 169 MTPA, enhancing backward integration and cost efficiency.